恩替卡韦或替诺福韦停药后2年内未再治疗患者的乙型肝炎病毒血症变化模式与乙型肝炎表面抗原清除率
研究纳入481例恩替卡韦或富马酸替诺福韦二吡呋酯停药后2年内未再治疗的患者,按HBV DNA和ALT水平分为四组。停药时HBsAg<150 vs ≥150 IU/mL者,停药后5年转为非活动期比例分别为57.2% vs 16.1%(P<0.001),HBsAg清除率分别为25.4% vs 4.7%(P=0.001)。保持或转为非活动期者HBsAg清除率较高。
要点
- 停药后2年内未再治疗者中,维持或转为非活动期与较高HBsAg清除率相关。
- 停药时HBsAg<150 vs ≥150 IU/mL者,5年HBsAg清除率25.4% vs 4.7%(P=0.001)。
- 停药时HBsAg<150 vs ≥150 IU/mL者,5年转为非活动期比例57.2% vs 16.1%(P<0.001)。
核心结论
- 停药后2年内未再治疗的患者中,保持或转为非活动期者HBsAg清除率较高。
研究设计与样本
- 研究纳入481例恩替卡韦或富马酸替诺福韦二吡呋酯停药后2年内未再治疗的患者。
主要发现
- 242例I组患者中,205例(84.7%)维持同一组,22例(9.1%)在2年后转为活动期。
- 239例II、III、IV组患者中,分别有33%、28.8%、31.1%在2年后转为非活动期。
- 停药时HBsAg<150 vs ≥150 IU/mL者,停药后5年转为非活动期比例57.2% vs 16.1%(P<0.001),HBsAg清除率25.4% vs 4.7%(P=0.001)。
- 维持非活动期的I组、转为非活动期的II+III组和IV组患者,停药后10年HBsAg清除率分别为57.7%、45.4%、55.1%(P=0.404)。
关键数值与推荐
- I组定义为HBV DNA<2,000 IU/mL且丙氨酸转氨酶<40 U/mL(非活动期)。
- II组定义为HBV DNA>2,000 IU/mL且ALT<40 U/L;III组为ALT 40-80 IU/mL;IV组为HBV DNA>2,000 IU/mL且ALT>80 U/mL(活动期)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study investigated the patterns of hepatitis B virus (HBV) viremia change and hepatitis B surface antigen (HBsAg) loss rate without retreatment within 2 years after nucleos(t)ide analog (NA) cessation. METHODS: We enrolled 481 patients who did not receive retreatment in the first 2 years after entecavir or tenofovir disoproxil fumarate cessation. RESULTS: Group I was defined as persistent HBV DNA <2,000 IU/mL and normal alanine transaminase < 40 U/mL (inactive phase); Group II and Group III, as HBV DNA >2,000 IU/mL and ALT <40 U/L (Group II) or alanine transaminase 40-80 IU/mL (Group III); and Group IV, as HBV DNA >2,000 IU/mL and ALT>80 U/mL (active phase). Of the 242 Group I patients, 205 (84.7%) remained in the same group and 22 (9.1%) transitioned to active phase beyond the first 2 years. Of the 239 Group II, III, and IV patients, 33%, 28.8%, and 31.1% patients transitioned to inactive phase beyond the first 2 years, respectively. Of the 239 patients who achieved HBsAg <150 vs ≧150 IU/mL at the end of treatment, the transition to inactive phase and HBsAg loss rates at year 5 after NA cessation were 57.2% vs 16.1% ( P < 0.001) and 25.4% vs 4.7%, respectively ( P = 0.001). The 10-year HBsAg loss rate after NA cessation for patients in Group I who remained in inactive phase, and Groups II + III and Group IV patients who transitioned to inactive phase were 57.7%, 45.4%, and 55.1% ( P = 0.404), respectively. DISCUSSION: Patients who remained or transitioned to the inactive phase had a high HBsAg loss rate without retreatment within 2 years after NA cessation.
引用
- Chen CH, Tai WC, Hu TH, et al. Patterns of Hepatitis B Virus Viremia Change and Hepatitis B Surface Antigen Loss Rate in Patients Without Retreatment Within 2 Years After Entecavir or Tenofovir Cessation. Am J Gastroenterol. 2025. PMID: 39996613. doi:10.14309/ajg.0000000000003372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。